Get the Stockscreener App
0.307
14.72%
-0.053
After Hours:
.30
-0.007
-2.28%
Eterna Therapeutics Inc stock is traded at $0.307, with a volume of 30.45M.
It is down -14.72% in the last 24 hours and down -71.31% over the past month.
See More
Previous Close:
$0.36
Open:
$0.4746
24h Volume:
30.45M
Relative Volume:
54.39
Market Cap:
$15.77M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0544
EPS:
-5.64
Net Cash Flow:
$-17.32M
1W Performance:
-30.23%
1M Performance:
-71.31%
6M Performance:
-84.38%
1Y Performance:
-74.63%
1-Day Range:
$0.30
$0.4988
1-Week Range:
$0.30
$0.4988
52-Week Range:
$0.30
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Name
Eterna Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Eterna Therapeutics Inc
|
0.307 | 15.77M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eterna Therapeutics Inc Stock (ERNA) Latest News
Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online
Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada
Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire
Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (Erna-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models - Marketscreener.com
ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com
ERNA stock touches 52-week low at $0.4 amid market challenges By Investing.com - Investing.com South Africa
Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa
Eterna Therapeutics initiates $1 million stock buyback - Investing.com India
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - GlobeNewswire
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges - Investing.com Australia
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges By Investing.com - Investing.com South Africa
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India
Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times
Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK
NTN Buzztime Enters Into Material Definitive Agreement and Reports Voting Results at Annual Meeting Eterna Therapeutics Inc., a company listed on the Nasdaq Stock Market under the symbol ERNA, recently filed a Form 8-K with the Securities - Defense World
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire
Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa
Eterna Therapeutics announces share issuance and executive agreements - Investing.com India
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna, Factor announce license, collaboration agreement - Yahoo Finance
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - BioSpace
Eterna secures exclusive license for cell therapy tech - Investing.com India
Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire
Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World
Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks
Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World
Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Eterna Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
3.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):